Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + irinotecan for platinum‑resistant esophageal or gastric cancer
2008-006168-12Phase 2Completed
- Sponsor
- University Hospital Odense
- Start
- Oct 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and irinotecan in esophageal cancer and gastric cancer (GC), sponsored by University Hospital Odense. Primary endpoints: Response rate and Time to progression. Started Oct 2008; status: completed.
02
Drugs
cetuximabirinotecan
03
Conditions
esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on 2008-006168-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006168-12.